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The classic neurotrophins Nerve Growth Factor (NGF), Brain Derived Neurotrophic Factor
(BDNF) and Neurotrophins NT-3 and NT-4 are well known to regulate various aspects of
neuronal differentiation, survival and growth. They do this by binding to their cognate
receptors, members of the Tropomyosin-related kinase (Trk) receptor tyrosine kinase
family, namely TrkA, TrkB, and TrkC. These receptors are then internalized and localized to
different cellular compartments, where signal transduction occurs. Conversely, members
of the suppressor of cytokine signaling (SOCS) family are best known as negative
regulators of signaling via the JAK/STAT pathway. Some members of the family, and in
particular SOCS2, have roles in the nervous system that at least partially overlap with that
of neurotrophins, namely neuronal differentiation and neurite outgrowth. Recent evidence
suggests that SOCS2 is a novel regulator of NGF signaling, altering TrkA cellular localization
and downstream signaling to affect neurite growth but not neuronal survival. This review
first discusses regulation of Trk receptor signaling, followed by the role of SOCS2 in the
nervous system and finishes with a discussion of possible mechanisms by which SOCS2
may regulate TrkA function.
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INTRODUCTION
A great deal of interest has focused on the therapeutic potential of
neurotrophins to prevent neurodegeneration and promote neural
regeneration in a range of neurological diseases and neurotrauma
(Allen et al., 2011; Colafrancesco and Villoslada, 2011; Ossipov,
2011; Duman and Voleti, 2012). Although administration of neu-
rotrophins, such as NGF, has promoted improvement in many
studies, their use as a therapeutic option is limited by unde-
sirable side-effects, such as neuropathic pain. Therefore, other
approaches to target neurotrophin receptors is required for ther-
apeutic purposes, to modulate specific aspects of neurotrophin
signaling that are beneficial and avoid those that are detrimen-
tal. To achieve this, a deeper understanding of the mechanisms
that regulate neurotrophin receptor function and signaling is
required. Here we describe the potential role of SOCS2 as a
novel regulator of NGF receptor (TrkA) signaling that differen-
tially affects NGF-mediated neurite outgrowth but not neuron
survival, altering TrkA protein levels, cellular localization and
extent and duration of specific NGF-induced signal transduction
pathways.
THE CLASSICAL NEUROTROPHINS AND THEIR RECEPTORS
The presence of a soluble factor capable of supporting the sur-
vival of motor and sensory neurons was first demonstrated in
1949 and prompted the characterization of NGF (Hamburger and
Levi-Montalcini, 1949; Levi-Montalcini, 1987), one of the earli-
est identified growth factors and the first member of the “classical
neurotrophin” family. In addition to its role in the peripheral ner-
vous system, NGF has been shown to have actions in the central
nervous system and the immune system (Dreyfus, 1989; Dreyfus
et al., 1989; Snider, 1994; Ernsberger, 2009; Scuri et al., 2010;
Allard et al., 2012). Three additional mammalian neurotrophic
factors have since been identified; brain-derived neurotrophic
factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5
(NT-4) (reviewed by (Reichardt, 2006; Skaper, 2012).
Neurotrophins signal through two-types of cell surface recep-
tor; the p75 neurotrophin receptor (p75NTR) (Radeke et al.,
1987; Bibel et al., 1999) and the Tropomyosin-related kinase
(Trk) receptor tyrosine kinases (Kaplan et al., 1991a,b; Klein
et al., 1991a). They bind with equal affinity to p75NTR (Radeke
et al., 1987; Rodriguez-Tebar et al., 1990; Hallbook et al., 1991;
Rodriguez-Tebar et al., 1992), however, the neurotrophins are
more selective in their interactions with the Trk receptors; TrkA
binds NGF, TrkB binds BDNF and NT-4/5 and TrkC binds NT-3
(Kaplan et al., 1991a,b; Klein et al., 1991a; Dechant et al., 1993;
Mahadeo et al., 1994). The mature neurotrophins form homod-
imers that can simultaneously bind two receptor molecules
(Barbacid et al., 1991; Heymach and Shooter, 1995). The Trk
receptors can form homodimers or can associate with p75NTR
(Bibel et al., 1999), thus a single neurotrophin dimer can simul-
taneously bind a Trk:Trk or Trk:p75NTR complex. When the Trks
form a co-receptor complex with p75NTR, lower concentrations
of the neurotrophic ligand are required to initiate signaling via
the Trk receptor than if the Trk receptors were solely expressed
(Mahadeo et al., 1994). The co-receptor Sortilin can also bind
the Trk receptors and has been implicated in the transport of
TrkA along axons (Vaegter et al., 2011). Beyond its involvement
in Trk and sortilin signaling, p75NTR has been implicated in the
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inhibition of axon growth and dendritic complexity by regulating
the GTPase RhoA (Yamashita et al., 1999, 2002; Zagrebelsky et al.,
2005).
SIGNALING EVENTS DOWNSTREAM OF THE Trk NEUROTROPHIN
RECEPTORS
A diverse range of cell responses can be initiated upon neu-
rotrophin binding. The type of signal is influenced by the combi-
nation of neurotrophin receptors presented on the cell membrane
and the unique collection of intracellular effectors that can be
recruited by the different receptors upon activation (Lee et al.,
2001; Huang and Reichardt, 2003). Signaling downstream of the
Trk receptors is a complex affair (Reichardt, 2006). The Trk recep-
tors possess a single transmembrane domain and an extracellular
ligand-binding domain comprising leucine-richmotifs (LRR1-3),
two cysteine clusters (C1 and C2) and two immunoglobulin-
like domains (Ig1 and Ig2) (Johnson et al., 1986; Radeke et al.,
1987; Schneider and Schweiger, 1991; Windisch et al., 1995a,b)
(Figure 1). The second immunoglobulin-like domain largely
dictates the neurotrophin-binding specificity of the Trk recep-
tors and there is some evidence that the immunoglobulin-like
domains serve to inhibit spontaneous dimerization of the Trk
receptors in the absence of ligand (Arevalo et al., 2000). Ligand
binding to the Trk receptors triggers receptor dimerization and
activation of the intrinsic cytoplasmic kinase domain and recep-
tor autophosphorylation. There are 10 known conserved tyrosine
residues on the cytoplasmic tail of the mammalian Trk recep-
tors, some of which are phosphorylated upon receptor activation
(Stephens et al., 1994; Inagaki et al., 1995). Three of these sites
are located in the auto-regulatory loop of the tyrosine kinase
domain and thus modulate kinase activity when phosphorylated.
The remaining phosphorylated tyrosine residues form binding
sites for scaffold proteins and enzymes that contain phosphotyro-
sine binding (PTB) domains or Src-homology-2 (SH2) domains
and the specificity of these interactions is tailored by the flank-
ing amino acids. The best characterized of these docking sites
are Y490 and Y785 as per the nomenclature of human TrkA, also
known as Y499 and Y794 in rat TrkA. The other conserved sites
have been shown to display some degree of functional redundancy
with respect to downstream signaling.
Activation of signaling pathways
The activated Trk receptors initiate diverse signaling pathways
downstream of Ras, phosphatidylinositol 3-kinase (PI3-kinase)
and phospholipase C- γ1 (PLC-γ1) (Figure 2) (Obermeier et al.,
1993a,b; Ong et al., 2000). These signaling components are com-
mon to many other growth factor and cytokine stimuli, thus there
is obviously scope for crosstalk between these diverse signaling
pathways. Both the Ras-MAPK and PI3-K/AKT pathways con-
verge on the common upstream scaffold protein, Src homologous
and collagen-like (Shc), which is known to recognize phosphory-
lated Y490 of the Trk receptors. This tyrosine residue is also well
characterized as a FRS2 binding site which can also promote the
prolonged activation of MAP kinases via recruitment of GRB2,
Crk and Src. PLC γ1 binds the activated TrkA receptor at Y785
and prompts increased Ca2+ levels which can influence synap-
tic plasticity and activation of protein kinase C (PKC) signaling
FIGURE 1 | Domain organization of the Trk neurotrophin receptors.
This figure highlights the key structural elements of the Trk neurotrophin
receptors; the extracellular ligand-binding domain comprising leucine-rich
motifs (LRR1-3), two cysteine clusters (C1 and C2) and two
immunoglobulin-like domains (Ig1 and Ig2), the transmembrane domain,
and the intracellular tyrosine kinase domain. Critical tyrosine residues of the
human TrkA intracellular domain are highlighted. Tyrosine residues at
positions 670, 674, and 675 are located in the activation loop of the human
TrkA tyrosine kinase domain. Tyrosine 490 forms a PTB binding motif
(NPXpY) known to bind SHC and FRS2 (Obermeier et al., 1993b; Ong et al.,
2000) and tyrosine 785 binds to PLCγ (Obermeier et al., 1993a). The
juxtamembrane KFG motif is an ubiquitination site involved in receptor
localization.
cascades to effect changes in transcription. The neurotrophins
are also known to activate members of the Rho GTPase family
such as Cdc42 and Rac that are regulators of the cytoskeletal rear-
rangements required for cell motility and the formation of growth
cones (Yuan et al., 2003).
A less established pathway downstream of the Trk recep-
tors is the activation of the signal transducer and activator
of transcription-3 (STAT3) transcription factor. Early studies
demonstrated that dominant negative STAT3 can promote PC12
neurite outgrowth in the absence of NGF (Ihara et al., 1997)
and STAT3 was identified as a downstream effector of Trk neu-
rotrophins in both PC12 cells and primary hippocampal neurons
(Ng et al., 2006). BDNF can induce proliferation of neural stem
cells via a mechanism involving MAP kinase, AKT and STAT3
activation (Islam et al., 2009) and constitutively active Trk recep-
tors can induce STAT3 activation (Miranda et al., 2010).
A variety of phosphatases are recruited to the Trk receptors.
The protein tyrosine phosphatase SH2 domain-containing phos-
phatase -2 (SHP-2) has been shown to have a transient association
with the Trk receptors upon neurotrophin binding (Okada et al.,
1996; Goldsmith and Koizumi, 1997) and provide an impor-
tant counterbalance to TrkB activation (Rusanescu et al., 2005).
SHP-2 may also be indirectly recruited to the Trk receptors via
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FIGURE 2 | Trk receptor signaling pathways. Upon neurotrophin
binding, the activated Trk receptors engage various intracellular signaling
pathways such as those mediated by extracellular signal-regulated
kinases (ERKs), phosphatidylinositol 3-kinase (PI3K) and phospholipase
Cγ (PLC-γ) to promote cellular differentiation, growth, survival, synaptic
plasticity and changes to cell motility (adapted from Huang and
Reichardt, 2003). Critical tyrosine (Y) residues of the human TrkA
intracellular domain are shown. Direct, indirect and inhibitory pathways
are denoted by solid arrows, dashed arrows and blunt arrows
respectively.
adapter molecules such as FRS2 (Yamamoto et al., 2005; Easton
et al., 2006) and NOMA-GAP (Rosario et al., 2007). The related
SHP-1 phosphatase has also been shown to bind TrkA at Y490
and dephosphorylate residues Y674 and Y675 in the TrkA tyro-
sine kinase activation loop (Marsh et al., 2003). The receptor-like
protein tyrosine phosphatase sigma (PTPsigma) can bind stably
to TrkA and TrkC via its transmembrane domain and dephos-
phorylate all the Trk receptors upon neurotrophin stimulation
(Faux et al., 2007). Another receptor-like phosphatase, the pro-
tein tyrosine phosphatase receptor zeta (PTPRz), can inhibit
phosphorylation of the activation loop tyrosine residues of the
TrkA receptor upon NGF stimulation (Shintani and Noda, 2008).
Interestingly, some phosphatases have a positive regulatory role
in TrkA signal transduction. The protein phosphatase 2A has been
shown to enhance the tyrosine kinase activity of the TrkA receptor
leading to sustained activation and downstream AKT and ERK1/2
activity, possibly mediated by dephosphorylation of inhibitory
serine and threonine phosphorylation sites (Van Kanegan and
Strack, 2009).
The activated Trk receptors can modulate the signaling of var-
ious ion channels and, even in the absence of neurotrophins, the
Trk receptors can be transactivated upon association with mem-
brane associated G-protein coupled receptors (GPCRs) (Chao,
2003). The juxtamembrane domain of TrkA has been shown to
interact with a PDZ domain-containing scaffold protein GIPC
that is also a component of a GPCR complex (Lou et al., 2001).
More recent studies have shown that GIPC is required for the effi-
cient trafficking and endocytosis of TrkA (Varsano et al., 2006).
This finding points to the critical role of receptor trafficking in
the modulation of Trk-mediated signaling.
NEUROTROPHIN RECEPTOR DYNAMICS AND THE UNIQUE CELL
BIOLOGY OF NEUROTROPHIN SIGNALING
The retrograde transport of neurotrophic stimuli has been most
extensively studied in the developing peripheral nervous system
and is critical for the formation and refinement of neuronal
circuits during development and for the regulation of synaptic
plasticity and neuronal survival in the mature nervous system
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(Huang and Reichardt, 2001; Zweifel et al., 2005). The mechanics
of this receptor trafficking have been scrutinized since retrograde
axonal transport of NGF was first demonstrated in 1974 (Hendry
et al., 1974; Paravicini et al., 1975; Johnson and Yip, 1985). Target
tissues secrete limiting amounts of neurotrophins and neighbor-
ing nerve terminals will transport this trophic signal to the distant
neuronal cell bodies and thus support the survival of the innervat-
ing neuron. The complex morphology of neurons poses specific
challenges for the transport of molecules from one part of the cell
to another, as axon lengths can be in excess of 1 meter in some
instances. Passive diffusion cannot account for the speed and dis-
tance travelled by these signals, and several different mechanisms
have been proposed for the propagation of NGF signals, how-
ever, a mounting body of evidence now supports a model of the
active retrograde transport of the neurotrophin signal in neurons
via “signaling endosomes” (reviewed by Howe and Mobley, 2005;
Ibanez, 2007; Wu et al., 2009; Ascano et al., 2012).
Neurotrophin receptor endocytosis
Clathrin-mediated endocytosis upon ligand binding is an impor-
tant mechanism for both the attenuation and propagation of
signals received by many receptor tyrosine kinases (McPherson
et al., 2001). A point of difference between the Trk receptors and
other receptor tyrosine kinases may be their ability to form long-
lived signaling endosomes due to a selective and specific process
of clathrin-independent macroendocytosis (Valdez et al., 2005,
2007). These specialized endosomes appear to retain association
with markers of early endosomes, and thus fail to mature to late
endosomes or progress to lysosomal degradation (Valdez et al.,
2005).
In neurons, neurotrophin binding to p75NTR or Trk receptors
at the axon terminal induces receptor-mediated endocytosis of
the activated receptor complex, and a subset of these internalized
receptors are retrogradely transported to the cell body in vesicles
that resemble early endosomes (Ehlers et al., 1995; Grimes et al.,
1996; Bhattacharyya et al., 1997; Tsui-Pierchala and Ginty, 1999;
Watson et al., 1999; Jullien et al., 2002, 2003; Delcroix et al., 2003).
These endosomes containing activated Trk receptors can associate
with the dynein motor and move along the axon toward the cell
body (Bhattacharyya et al., 2002). Data from compartmentalized
cultures revealed that NGF applied to the distal axons of sympa-
thetic neurons can support their survival. However, the addition
of the specific Trk kinase inhibitor K252a to either the distal axon
or the cell body compartment induced cell death suggesting that
activated TrkA was required for propagation of the survival signal
into the cell and that the downstream effectors of TrkA signaling
could not propagate the signal in the absence of activated TrkA
and NGF must be retained in the signaling endosomes for the
TrkA survival signal to persist (Ye et al., 2003).
INTRACELLULAR LOCALIZATION OF INTERNALIZED Trk RECEPTORS
Upon receptor internalization, the exposed cytoplasmic domains
of receptor tyrosine kinases can interact with different inter-
mediates found in different subcellular locations, and thereby
fine-tune the signaling output of the activated receptors (reviewed
by Romanelli and Wood, 2008; Acconcia et al., 2009; Disanza
et al., 2009; Sadowski et al., 2009). An example of differential
signaling based on altered subcellular localization of activated
NGF-TrkA complexes comes from the PC12 cell line that is a
useful model of neuronal-like differentiation. PC12 cells express
both TrkA and p75NTR and upon serum withdrawal and treat-
ment with NGF, undergo mitotic arrest and extend neurites
(Greene and Tischler, 1976; Greene, 1978). It has been demon-
strated that in PC12 cells internalization of the activated NGF:
TrkA complex is required for the induction of neurite outgrowth
but not NGF-mediated survival, suggesting that the intracellu-
lar localization of the activated receptors can influence the type
of signaling output (Zhang et al., 2000). Activated Trk recep-
tors located at the cell surface promote cell survival signaling via
PI3-K/AKT activation whereas Trk receptors signaling from inter-
nalized endosomes promote cell differentiation by preferential
activation of MEK/ERK pathways (Zhang et al., 2000). A con-
flicting report using sciatic nerves showed that the p85 subunit of
the PI3-K signaling cascade is associated with internal membrane
compartments such as early endosomes (Delcroix et al., 2003).
It appears that activated Trk receptors are localized to different
membrane fractions when comparing PC12 cells and primary
neurons (Yano and Chao, 2005), so this may underlie the appar-
ent discrepancy regarding the types of Trk signaling observed in
different subcellular locations.
Specific sequences in the cytoplasmic tail of the receptor tyro-
sine kinases can regulate the targeting of receptors to particular
compartments within the cell. In the case of TrkA, a juxtamem-
brane portion of the receptor between amino acids 473 and 493,
that is not present in TrkB or TrkC, is required for NGF-induced
recycling of the rat TrkA receptor (Chen et al., 2005). Treatment of
primary sympathetic neurons with NGF induced recycling of the
TrkA receptor, however application of BDNF induced the degra-
dation of the TrkB receptor. Modification of the TrkB receptor
to include this juxtamembrane region from TrkA resulted in the
ligand-induced recycling of the modified TrkB receptor.
Ubiquitination of Trk receptors
Ubiquitination has also emerged as a very important molec-
ular identifier for the intracellular trafficking of receptor
tyrosine kinases including TrkA (Acconcia et al., 2009).
Ubiquitin is a polypeptide that can be coupled to proteins
via lysine residue modification catalyzed by ubiquitin-activating
enzymes, ubiquitin-conjugating enzymes, and ubiquitin ligase
enzymes (Komander and Rape, 2012). The different molec-
ular conformations adopted by the different types of ubiq-
uitin labeling can encode various outcomes such as protein
degradation, protein activation, altered protein-protein interac-
tions and altered intracellular trafficking (Komander and Rape,
2012). Mono-ubiquitination is defined as the coupling of a
single ubiquitin moiety to lysine residues on the target pro-
tein. Poly-ubiquitination is the coupling of chains of ubiquitin
and the topology of these ubiquitin chains has been thought
to dictate proteolytic versus non-proteolytic downstream conse-
quences. The internalization of NGF-TrkA has been shown to
be regulated by the poly-ubiquitination of TrkA by the ubiquitin
ligase TRAF6 in PC12 cells (Geetha et al., 2005) whereas stim-
ulation of PC12 cells and primary cortical neurons with NGF
and BDNF has been shown to promote ubiquitination of both
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TrkA and TrkB, primarily taking the form of multiple sites of
mono-ubiquitination rather than poly-ubiquitination (Arevalo
et al., 2006). Proteasome inhibition appears to induce neurite out-
growth through TrkA receptor ubiquitination (Song et al., 2009)
and recent studies have also highlighted that the proper traffick-
ing of the activated TrkA receptor is essential for NGF-mediated
signaling in cultured dorsal root ganglion (DRG) neurons and is
regulated by multiple sites of mono-ubiquitination by the ubiq-
uitin ligase Nedd4-2 (Georgieva et al., 2011; Yu et al., 2011).
The ubiquitin ligase Cbl has also been implicated in the ligand-
dependent ubiquitination of TrkA and subsequent targeting of
the receptor to lysosomes for degradation (Takahashi et al., 2011).
Clearly ubiquitination and endosomal sorting both have impor-
tant roles to play in neurotrophin signaling, however, there is
still scope for more detailed exploration of the precise molecular
mechanisms involved.
Members of the suppressor of cytokine signaling (SOCS) fam-
ily have recently emerged as ubiquitin ligases regulating expres-
sion of a variety of receptors and their signaling pathways. One
member of this family in particular, SOCS2, has a variety of
functions in the nervous system, many of which overlap with
the biological effects of TrkA signaling, suggesting a possible
regulatory role for SOCS2 in TrkA function.
THE SUPPRESSORS OF CYTOKINE SIGNALING (SOCS) IN
THE NERVOUS SYSTEM
The SOCS proteins are a family of intracellular proteins impli-
cated in the negative regulation of a variety of cytokine, growth
factor and hormone signals, particularly those mediated by the
Janus kinase/signal transducer and activator of transcription
(JAK/STAT) signaling pathway (O’Sullivan et al., 2007; Croker
et al., 2008; Piessevaux et al., 2008a).
The SOCS proteins have pleiotropic effects in the healthy and
diseased nervous system (Wang and Campbell, 2002; Campbell,
2005). They have been implicated in the regulation of diverse cel-
lular processes including neurodevelopment (Turnley et al., 2001;
Feng et al., 2007), adult neurogenesis (Ransome and Turnley,
2007), neuroinflammation (Turnley et al., 2002a; Baker et al.,
2009; Campbell et al., 2010; Gilli et al., 2010, 2011) and neuro-
trauma (Stark and Cross, 2006; Qin et al., 2008; Choi et al., 2009;
Girolami et al., 2010; Hellstrom et al., 2011). Consistent with
the emerging link between excessive inflammation and neurode-
generative disorders (Frank-Cannon et al., 2009), there is now
evidence that the SOCS proteins might also have a role to play
in the progression of neurodegenerative disorders (Ghosh and
Pahan, 2012). In many of the studies cited, the SOCS proteins
have been implicated as regulators of inflammatory responses
in the central nervous system, however it is important to note
that the SOCS proteins also demonstrate neural specific functions
in neuronal differentiation. SOCS2 is one member of the SOCS
family that is recognized as an important regulator of neuronal
function.
BIOCHEMISTRY OF THE SOCS PROTEINS—GENERAL
The role of the SOCS proteins has been most extensively stud-
ied in the context of cytokine signaling via receptors that lack
intrinsic tyrosine kinase activity that recruit effectors such as
the cytoplasmic Janus kinases (JAKs) (O’Sullivan et al., 2007).
Cytokine binding to the receptor at the cell surface promotes asso-
ciation of the receptor subunits and signals a cascade of down-
stream phosphorylation events. This signaling pathway begins
with the cross-phosphorylation and activation of the receptor-
associated JAKs. The JAKs in turn phosphorylate sites on the
cytoplasmic tails of the activated receptors thereby creating dock-
ing sites for the STAT proteins. Recruitment of these transcription
factors is followed by the phosphorylation and dimerization of the
STATs. Activated STAT dimers translocate to the nucleus where
they can initiate transcription of a variety of genes responsible for
survival and proliferation. STAT activation also promotes tran-
scription of negative regulators such as the SOCS family that can
suppress further signaling and thus restore sensitivity of the cell
to future cytokine stimuli.
The SOCS proteins were first identified as cytokine-
inducible inhibitors of signaling with the characterization of CIS
(Yoshimura et al., 1995) and SOCS1 (Endo et al., 1997; Naka et al.,
1997; Starr et al., 1997). There are several modes by which the
SOCS proteins can inhibit cytokine signaling; competition for
STAT binding sites, binding to activated receptors or JAKs and
promoting their degradation by the proteasome or direct inhibi-
tion of the catalytic site of the JAKs (Figure 3). SOCS proteins
can inhibit the downstream effectors of the cytokine stimulus
that promoted their initial induction (i.e., “negative feedback”)
or inhibit signaling intermediates downstream of independent
cytokine stimuli (i.e., “cross-talk”).
Each of the 8 SOCS proteins (SOCS1-7 and CIS) comprise
a variable N-terminal region, a central Src Homology 2 (SH2)
domain and a highly conserved C-terminal SOCS box (Figure 4).
SH2 domains recognize and bind to specific tyrosine phosphory-
lated motifs within proteins whilst the SOCS box motif interacts
with E3 ubiquitin ligases thereby targeting any SOCS-associated
proteins for degradation by the proteasome (Kamura et al., 1998;
Zhang et al., 1999; Krebs et al., 2002). Pairs of SOCS pro-
teins show varying degrees of similarity in their primary amino
acid sequence, suggestive of a degree of functional redundancy
amongst members of the family (Hilton et al., 1998). The crys-
tal structures of SOCS2 (Bullock et al., 2006), SOCS3 (Babon
et al., 2008) and SOCS4 (Bullock et al., 2007) in complex with
elongin BC have been solved. In addition, in vitro studies uti-
lizing recombinant purified proteins have demonstrated that the
SOCS box motifs of all the SOCS proteins recruit elongin BC
before binding Cullin5, an E3 ubiquitin ligase scaffold protein
(Babon et al., 2009). A region immediately upstream of the clas-
sical SH2 domain, known as the extended SH2 subdomain (ESS),
appears crucial to the formation of a stable interface between the
SOCS box and the SH2 domain in a subset of the SOCS fam-
ily comprising CIS, SOCS1, SOCS2, and SOCS3 (Bullock et al.,
2006).
The SOCS proteins couple specific phosphotyrosine-motif
recognition with ubiquitin-ligase activity and are thus potent
inhibitors of a variety of cytokine signaling pathways. As previ-
ously mentioned, the SOCS proteins can participate in “negative
feedback” inhibition or “cross-talk” suppression of independent
cytokine stimuli. This cross-talk has been shown to extend to
the cross regulation amongst the SOCS proteins. SOCS2, SOCS6,
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FIGURE 3 | Inhibition of JAK-STAT cytokine signaling by the SOCS
proteins. The different SOCS proteins can inhibit JAK-STAT signaling via
different mechanisms including competition for STAT binding sites on
activated receptors, direct inhibition of JAK kinase activity or targeting of
associated signaling molecules for proteasomal degradation. Adapted from
Palmer and Restifo (2009).
and SOCS7 appear to form a subgroup of the SOCS family that
have been shown to interact with the SOCS box of all members
of the SOCS family and may be required to regulate the stabil-
ity of other SOCS proteins (Piessevaux et al., 2006). This cross
regulation might enable late-induction SOCS proteins (such as
SOCS2) to down regulate early-induction SOCS proteins (such
as CIS, SOCS1, and SOCS3) so the cell can restore sensitivity
to future cytokine stimulation (Tannahill et al., 2005; Piessevaux
et al., 2006).
The regulation of receptor trafficking by the SOCS proteins
The SOCS proteins typically act by regulating the ubiquitin
tagging of signaling intermediates to promote their proteasome-
dependent degradation and thus suppress further signaling. As
previously mentioned, a more complex role for post-translational
modifications such as ubiquitination has emerged whereby the
type and extent of ubiquitin tagging can also dictate the sorting
of membrane-associated proteins to early endosomes which can
continue to signal after internalization. It is intriguing to specu-
late the important role that ubiquitin-ligases such as the SOCS
proteins may play in both determining the strength or duration
of signaling events, and fine-tuning the type of responses of cells
such as neurons to extracellular cytokine stimuli. One example
that implicates the SOCS proteins in this receptor trafficking role
has been observed in the SOCS3 dependent transport of the gran-
ulocyte colony stimulating factor receptor (G-CSFR) (Irandoust
et al., 2007). G-CSFR transport from the early endosomes to
the lysosomes was impaired when a membrane-proximal lysine
residue of the G-CSFR was mutated to prevent ubiquitin conjuga-
tion at this site and altered ubiquitin conjugation of this receptor
resulted in altered intracellular signaling outcomes.
THE BIOCHEMISTRY OF SOCS2
SOCS2 was isolated in a yeast-two-hybrid screen in which the
cytoplasmic domain of the insulin-like growth factor-1 (IGF-1)
receptor was used as bait to screen a cDNA library of proteins
expressed in the human fetal brain (Dey et al., 1998). IGF-1
is a second messenger of GH and the essential role of SOCS2
in the negative regulation of the GH/IGF-1 pathway was subse-
quently validated in vivo by the phenotype of the SOCS2KO mice
(Metcalf et al., 2000). The activated GHR engages the JAK/STAT
pathway and accordingly the observed induction of SOCS2 by
GH (Adams et al., 1998; Tollet-Egnell et al., 1999) is supported
by the presence of putative STAT5 transcription factor binding
sites, amongst others, in the vicinity of the Socs2 gene (Laz et al.,
2009).
The transfection of 293T cells with a series of SOCS2 dele-
tion constructs in addition to the GH receptor highlighted the
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FIGURE 4 | Domain organization of the SOCS proteins. Each of the 8
SOCS proteins (SOCS1-7 and CIS) comprise a variable N-terminal region, a
central Src Homology 2 (SH2) domain to recognize motifs containing
phosphorylated tyrosine residues and a highly conserved C-terminal SOCS
box to facilitate association with components of the ubiquitin ligase
machinery such as elongin BC and cullin5. The kinase inhibitory region (KIR)
(Sasaki et al., 1999; Yasukawa et al., 1999; Kershaw et al., 2013) within the
extended SH2 subdomain (ESS) of SOCS1 and SOCS3 are denoted by an
asterisk. The most closely related pairs of SOCS proteins according to
amino acid sequence similarity are denoted on the right.
structural motifs required for the SOCS2 downregulation of sig-
naling via the GH receptor (Greenhalgh et al., 2005). Removal
of the SOCS2 N-terminus relieved inhibition of GH signaling
and point mutation of critically conserved residues within the
phosphotyrosine-binding pocket of the SH2 domain produced
partial or complete loss of inhibitory function. Furthermore,
deletion of the SOCS box relieved inhibition of GH signaling and
actually resulted in enhanced signaling even at low concentra-
tions. The inhibitory role of SOCS2 has been shown to rely on
the C-terminal SOCS box in the case of proteasomal degrada-
tion of the phosphorylated proline-rich tyrosine kinase 2 (Pyk2)
(Lee et al., 2010). The most recent development in our under-
standing of SOCS2 biochemistry came with the demonstration
that SOCS2 can directly regulate the levels of the growth hormone
receptor in a 293T overexpression system (Vesterlund et al., 2011).
The SOCS2 ubiquitin ligase complex was shown to directly ubiq-
uitinate the GH receptor and co-expression of SOCS2 decreased
the half-life of the GHR. This effect of SOCS2 overexpression was
removed by inhibition of the proteasome and mutation of GHR
at Y487 and an intact SOCS box was required for the stabilization
of the SOCS2-ubiquitin ligase complex.
Overexpression of SOCS2, both in vivo and in vitro, has
unveiled a complex role for SOCS2 in the modulation of GH sig-
naling and it is clear that SOCS2 can both inhibit and enhance
GH signaling (Favre et al., 1999; Greenhalgh et al., 2002a). There
are several explanations for the enhancement of GH signaling
observed when SOCS2 is overexpressed. It is possible that the
overexpressed FLAG-SOCS2 used in the in vitro studies is non-
functional and inhibiting the role of endogenous SOCS2, thus the
overexpressed SOCS2 is acting as a dominant-negative mutant
(Greenhalgh et al., 2002a). Alternatively, at high concentrations
SOCS2 might be competing for SOCS3 binding sites on the GH
receptor (residues Y332 and Y487) and since SOCS3 is consid-
ered a more potent inhibitor of GH signaling, displacing SOCS3
from these binding sites might indirectly enhance GH signal-
ing (Greenhalgh et al., 2002a). Other groups (Tannahill et al.,
2005; Piessevaux et al., 2008a) propose that since SOCS2 can
bind all members of the SOCS family, SOCS2 may accelerate the
turnover of other SOCS proteins via a “cross-regulatory mecha-
nism” that would allow SOCS2 to enhance cytokine responses by
accelerating proteasome-dependent turnover of SOCS3. In addi-
tion, binding to elongin BC has been shown to be essential for the
proper folding and substrate recognition by the SOCS protein CIS
(Piessevaux et al., 2008b). If the pool of available elongin BC were
depleted by binding to overexpressed SOCS2, this may indirectly
enhance cytokine responses that would normally be suppressed
by other SOCS proteins.
SOCS2 AND MOUSE BIOLOGY—GENERAL
SOCS2 was initially characterized as a negative regulator of
growth hormone (GH) signaling (Metcalf et al., 2000). The
SOCS2 mediated downregulation of GH signaling is best demon-
strated by the gigantism phenotype of mice lacking SOCS2
(Metcalf et al., 2000). The SOCS2KO mice were approxi-
mately 40% heavier by 6 weeks of age and this corresponded
to an increase in bone length and the size of most organs,
although no hematological abnormalities were observed. The
difference in body size was accelerated at about 3–4 weeks
of age, and this was noted as the time point at which
growth hormone receptor is upregulated in many tissues (Shoba
et al., 1999). Other aspects of the SOCS2KO phenotype that
suggested a role for SOCS2 in GH signaling included an
increase in the levels of the GH second messenger insulin-
like growth factor-1 (IGF-1), decreased levels of major uri-
nary protein and thickening of the skin due to collagen
accumulation.
Mice lacking both STAT5b and SOCS2 and were found to
grow normally (Greenhalgh et al., 2002b) which suggested that
the SOCS2 modulation of JAK/STAT signaling downstream of
the GH receptor depends on the activity of STAT5b. Accordingly,
SOCS2 has been shown to interact with the GH receptor in vivo
and with STAT5b binding sites on the cytoplasmic tail of the GH
receptor (Y487 and Y495) in vitro (Greenhalgh et al., 2005). The
importance of SOCS2 as a negative regulator of GH signaling
in vivo was further exemplified by the absence of the SOCS2KO
phenotype when endogenous GH was also removed (Greenhalgh
et al., 2005).
Given that the SOCS2KO mice were hyper-responsive to GH
signaling, it was presumed that increased SOCS2 expression
would yield mice hypo-responsive to GH signaling with a phe-
notype similar to the dwarfism observed in GH receptor knock-
out mice (Zhou et al., 1997). On the contrary, transgenic mice
that overexpress SOCS2 (SOCS2TG) displayed a modest over-
growth phenotype indicating that when SOCS2 is either absent
or expressed at high levels there is enhanced signaling via the GH
receptor (Greenhalgh et al., 2002a). Whilst the SOCS2TG mice
were approximately 15% heavier at 3 weeks of age, they did not
display any other abnormalities with respect to specific tissues or
hematopoietic profile.
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SOCS2 AND NEUROBIOLOGY
Neuronal expression profile of SOCS2; probable roles in neuronal
proliferation and differentiation
SOCS2 is notable for the high levels of RNA expression in neurons
of the developing and adult mouse brain, and interestingly the
onset of SOCS2 expression appears to coincide with that of neu-
ronal differentiation (Polizzotto et al., 2000). The neural specific
expression of SOCS2 during development prompted investiga-
tion into the role of SOCS2 in neuronal differentiation. SOCS2
is expressed in neural stem cells and neurons most highly at E14
which is a time point that coincides with a peak in neuronal
generation (Polizzotto et al., 2000). More detailed in vitro anal-
ysis of the neuronal expression profile of SOCS2 revealed that
it is expressed in cultured embryonic day 10 (E10) neuroepithe-
lial cells and E17 cortical neurons but not cortical astrocytes or
adult multipotent stem cells (Turnley et al., 2002b). In the neu-
roepithelial cultures, Socs2 gene expression was increased above
basal levels by the addition of LIF, interferon gamma, OsM and
CNTF, and LIF promoted Socs2 gene expression in E17 cortical
neuron cultures (Turnley et al., 2002b). Notably, growth hor-
mone (GH) did not influence Socs2 expression in either cell
type (Turnley et al., 2002b) unlike previous studies in which
GH induced expression of several SOCS proteins including CIS,
SOCS1, SOCS2 and SOCS3 in non-neuronal cell lines and tissues
(Adams et al., 1998; Tollet-Egnell et al., 1999). A link between
SOCS2 and the transcriptional regulation of neurogenesis has
been found in the GH regulation of the proneurogenic basic
helix loop helix transcription factor Neurogenin-1 (Turnley et al.,
2002b).
Neuroanatomical consequences of SOCS2 overexpression
Mice with altered growth hormone responsiveness, including
SOCS2KO (hyper-responsive), SOCS2TG (hypo-responsive) and
GH receptor null (GHRKO) (non-responsive) mice, exhibit a
variety of alterations in neural architecture (Ransome et al., 2004;
Ransome and Turnley, 2005). The changes in neural architecture
observed in SOCS2TG and SOCS2KO mice implicate this gene
in neuronal differentiation and neurite outgrowth. Interestingly,
despite the fact that loss of SOCS2 has an effect on mouse body
and organ size (Metcalf et al., 2000), it has no effect on brain size,
although there was an effect on neuronal density and composi-
tion (Ransome et al., 2004; Ransome and Turnley, 2005). The
SOCS2KO mice have decreased cortical neuron density whereas
the SOCS2TG and GHRKO mice exhibit an increased cortical
neuron density. The SOCS2TGmice have increased synaptic den-
sity and dendritic branching in the cortex, in contrast to the
sparse dendritic branching of pyramidal neurons in the cortex
of the SOCS2KO and GHRKO mice. Further, SOCS2TG mice
and GHRKOmice had markedly increased numbers of Calretinin
and Calbindin positive cortical interneurons, although expres-
sion of other markers, such as Parvalbumin and somatostatin
were not significantly altered. Furthermore, the overall number of
gamma-aminobutyric acid positive interneurons did not appear
to change between genotypes. The altered expression of cortical
interneuron markers observed in SOCS2TG and SOCS2KO mice
suggests that SOCS2 may regulate expression of specific tran-
scription factors required for interneuron subtype specification or
that expression of the interneuron markers might be modulated
by the amount of synaptic activity within a cell and thus the
altered levels of expression in the SOCS2TG and SOCS2KO mice
might simply arise from changes in neuronal circuitry and synap-
tic activity (Ransome and Turnley, 2005). Juxtaposition of the
neuroanatomical phenotypes of mice with altered responsiveness
to GH signaling (SOCS2KO hyper-responsive> SOCS2TG hypo-
responsive>GHRKO non-responsive) reveals that whilst cortical
neuron density correlates with increasing responsiveness to GH,
the measures of dendritic branching or some interneuron pop-
ulations do not. This invites speculation that SOCS2 can also
modulate other signaling events independent of GH signaling in
neural cells.
SOCS2 and neurite outgrowth
The proper formation of connections between cells of the nervous
system is critically dependent upon the extension of processes
or “neurites” at the surface of neurons. As mentioned previ-
ously, a useful model of neuronal-like differentiation is the PC12
cell line derived from a rat pheochromocytoma that undergoes
mitotic arrest and extends neurites when serum is withdrawn
and NGF is applied (Greene and Tischler, 1976; Greene, 1978).
Recent evidence suggests that SOCS2 may play a role in neu-
rite initiation as well as regulating neurite length. Overexpression
of SOCS2 in PC12 cells induces neurite outgrowth under non-
differentiating conditions (Goldshmit et al., 2004a) and primary
cortical neurons derived from transgenic mice that overexpress
SOCS2 demonstrate an increase in neurite length and neurite
number (Goldshmit et al., 2004b). Despite the fact that SOCS2
is required to overcome the inhibitory effects of GH on neuronal
differentiation, SOCS2 has also been shown to enhance neurite
outgrowth in neurons derived from neural progenitor cells and
this activity was not inhibited by the addition of GH (Scott et al.,
2006). These data suggest that the mechanisms by which SOCS2
regulates neuronal differentiation and neurite outgrowth may be
independent.
Since these initial reports of SOCS2 involvement in neurite
outgrowth, there have been other studies implicating various
members of the SOCS family in neurite outgrowth including
SOCS3 and SOCS6 (Miao et al., 2006; Gupta et al., 2011). SOCS7
may also emerge as an important regulator of neurite outgrowth
as it has been identified as an Nck interacting protein (Kremer
et al., 2007) and overexpression of Nck in the PC12 cell line has
been shown to enhance proliferation and block NGF and bFGF
induced differentiation by a MAPK independent mechanism
(Rockow et al., 1996).
SOCS2 AS A NOVEL REGULATOR OF TrkA LOCALIZATION
AND SIGNALING
While SOCS2 has broad ranging effects on neuronal differenti-
ation, maturation and survival, the molecular basis for SOCS2
activity in neurons is still largely unresolved. An altered respon-
siveness to GH does not appear to address all the changes
observed in the neural architecture of SOCS2KO and SOCS2TG
mice or the enhanced neurite outgrowth in neurons derived from
neural progenitor cells. Previous studies showed that overex-
pression of SOCS2 in PC12 cells resulted in enhanced neurite
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outgrowth, and this response was enhanced by the addition of
NGF (Goldshmit et al., 2004a). Thus, the possibility that SOCS2
might be regulating the neuronal response to NGF prompted
further investigation.
Neonatal dorsal root ganglia (DRG) contain a large population
of TrkA+ neurons that require NGF for survival and promotion
of neurite outgrowth. Analysis of DRG neuron cultures derived
from SOCS2TG and SOCS2KO mice showed that increased or
no expression SOCS2 respectively, regulated NGF-mediated neu-
rite outgrowth, with SOCS2 overexpression increasing and lack
of SOCS2 decreasing neurite length and complexity (Uren et al.,
2014). Surprisingly however, SOCS2 overexpression did not influ-
ence NGF-induced survival of DRG neurons, suggesting that
SOCS2 differentially regulates TrkA-related signal transduction
pathways. In order to try to dissect the mechanisms by which
this differential regulation occurred, a range of binding stud-
ies, expression and signal transduction analyses were performed
using SOCS2 and TrkA transfected 293T cells (contain no endoge-
nous TrkA), SOCS2 transfected PC12 cells (contain endogenous
TrkA and SOCS2) and SOCS2TG and wildtype DRG neurons
(contain endogenous TrkA and SOCS2).
Co-immunoprecipitation of SOCS2 and TrkA mutant pro-
teins in 293T cells showed that the juxtamembrane region of
TrkA was required for binding of SOCS2, with possible involve-
ment of the kinase domain as well. Overexpression of SOCS2
increased total TrkA levels in transfected 293T cells and PC12
cells and increased cell surface expression of TrkA in PC12 cells
and SOCS2TG DRG neurons (Uren et al., 2014), suggesting that
SOCS2 regulates TrkA protein turnover and cellular localization.
Further, SOCS2 overexpression increased the extent and dura-
tion of NGF-induced activation of signal transduction pathways
involved in neurite outgrowth such as ERK1/2 and pAKT (Uren
et al., 2014). These effects of SOCS2 on NGF mediated neurite
outgrowth but not survival, with altered TrkA surface expression
and enhanced signal transduction pathways are summarized in
Table 1.
While the mechanism by which SOCS2 regulates TrkA sig-
naling and functional outcome remains to be determined, it
most likely revolves around altered TrkA localization induced by
SOCS2-mediated ubiquitination. This could regulate the amount
of TrkA receptor at the cell surface and influence the rate at
which it is internalized, recycled, or transported to different intra-
cellular compartments, thereby modulating sensitivity of a cell
to NGF and altering downstream signal transduction pathways.
Ubiquitination of the lysine in the TrkA juxtamembrane KFG
motif regulates TrkA expression levels and localization, with dele-
tion of this domain leading to decreased ubiquitination, increased
TrkA levels and increased phosphorylation of the AKT and MAP
kinase pathways (Kiris et al., 2014), mirroring the effects of
SOCS2 overexpression (Uren et al., 2014). While SOCS2 was able
to bind to TrkA with the KFG domain deleted (TrkA450–452)
further functional effects of this deletion on TrkA expression,
localization or functional effects such as neurite outgrowth were
not examined (Uren et al., 2014). However, the similarity between
findings when SOCS2 is overexpressed or the TrkA KFG domain
is deleted suggests that regulation of ubiquitination by SOCS2,
either directly or indirectly, at the KFG motif may be at least part
Table 1 | SOCS2:TrkA interaction and outcome summary.
Outcome of increased SOCS2 expression




























Increased expression of SOCS2 (relative to endogenous levels of SOCS2), either
in SOCS2TG mice (DRG neurons) or by transfection of cell lines (PC12 and 293T
cells) alters the outcome of NGF-induced signaling. Increased SOCS2 does not
affect NGF-mediated DRG neuron survival, with equivalent levels of survival with
NGF and cell death in the absence of NGF. However, increased SOCS2 levels
promote increased neurite outgrowth under basal conditions, which is further
enhanced by NGF. It also increases total and surface TrkA levels (in PC12 cells
the increased surface levels correlate with increased total levels) and increases
the level and duration of signaling via the PI-3 kinase (AKT) and ERK1/2 path-
ways. The mechanism for this differential outcome of SOCS2 on NGF-mediated
survival vs. neurite outgrowth remains to be determined, as does how SOCS2
influences neurite outgrowth, but likely involves ubiquitination and altered TrkA
cellular localization due to the E3 ubiquitin ligase activity of the SOCS box.
of the mechanism regulating TrkA localization, expression levels
and downstream signal transduction. Interestingly, the converse
effects of decreased surface TrkA levels have also been described.
Depletion of NHE5 [a Na(+)/H(+) exchanger that acidifies recy-
cling endosomes to promote cell surface expression] resulted in
decreased levels of TrkA at the cell surface in PC12 cells, with
concomitant decreased phosphorylation of AKT and ERK1/2
and decreased neurite outgrowth in response to NGF treatment
(Diering et al., 2013).
CONCLUSIONS
Neurotrophins and their receptors are expressed in specific areas
throughout the nervous system. Their expression levels, signal
transduction pathways and localization are tightly regulated by
a range of different mechanisms, including dephosphorylation
and degradation. SOCS proteins are best known for their role as
negative feedback inhibitors of cytokine signaling but have been
shown to have a range of other roles, depending on cell type
and receptor under study. Their structure, which includes an SH2
interaction domain and the SOCS box ubiquitin ligase interaction
domain, suggests that they may interact with many more pro-
teins. This certainly appears to be the case for the TrkA receptor
and SOCS2. However, given that SOCS2 has also been shown to
bind to the BDNF and NT-3 neurotrophin receptors (Uren et al.,
2014), it is possible that SOCS2 plays even broader roles in reg-
ulation of neurotrophin signaling. Further, such crosstalk is not
necessarily confined to the nervous system and may play a role in
hematopoiesis, given the expression and function of Trk receptors
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in early hematopoietic cells (Chevalier et al., 1994; Ip, 1998; Li
et al., 2009; Rezaee et al., 2010). While the mechanisms remain
to be determined, SOCS2 and perhaps other SOCS molecules
may provide new therapeutic targets for regulation of pathologi-
cal signaling via neurotrophin receptors and suggests that further
research into the field is warranted.
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